• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis
【24h】

The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis

机译：抗IL-4受体α抗体dupilumab：面对治疗特应性皮炎的新时代

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Atopic dermatitis is the most common chronic inflammatory skin disease with high prevalence rates in adults and even higher among children. For the numerous patients suffering from moderate to severe disease, standard systemic treatment regimens such as cyclosporine A, methotrexate or azathioprine are not suited for long-term treatment due to their unfavorable safety profile. A promising alternative would be the newly developed IL-4 receptor alpha antibody dupilumab which has been investigated in several clinical trials during the last years.
机译：简介：特应性皮炎是最常见的慢性炎症性皮肤病，在成年人中患病率很高，在儿童中甚至更高。对于众多患有中度至重度疾病的患者，标准的全身治疗方案（例如环孢素A，甲氨蝶呤或硫唑嘌呤）由于其不良的安全性而不适用于长期治疗。一种有希望的替代方法是新近开发的IL-4受体α抗体dupilumab，最近几年已在多项临床试验中对其进行了研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号